Biomarker ID | 910 |
PMID | 22542564 |
Year | 2012 |
Biomarker | PCA3 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Urine |
Subjects | Humans |
Regulation | Upreregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | PCa VS No PCa group |
Type of Biomarker | Diagnostic |
Cohort | 67 patients with Benign Prostatic Hyperplasia, 36 with High Grade PIN, and 48 with Prostate Cancer were selected for the study. |
Senstivity | 0.81 [95% CI: 0.68–0.91] |
Specificity | 0.57 [95% CI: 0.45–0.69] |
AUC | 0.71 |
Accuracy | NA |
Level Of Significance | p< 0.001 |
Method Used | Progensa PCA3 assay |
Clinical | No |
Remarks | PCA3 score is calculated as [(PCA3 mRNA / PSA mRNA) × 1000] |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | PCA3 |